extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
1e8be39f7f
commit
db7f39b9ea
5 changed files with 64 additions and 1 deletions
|
|
@ -41,6 +41,12 @@ MA plans' near-universal prior authorization creates administrative friction tha
|
|||
|
||||
MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump Administration's November 2025 deal establishes $245/month Medicare pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—the highest-risk patients where downstream savings (dialysis delay, cardiovascular event reduction) are most likely to offset drug costs under capitated payment. The 'inflationary through 2035' conclusion assumed higher prices and broader populations; narrow targeting of high-risk patients may make this cost-neutral under capitation even if system-level impact remains inflationary.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
Medicare's eligibility criteria exclude simple obesity patients, instead requiring comorbidities (prediabetes, CVD, heart failure, hypertension, CKD). This population may have higher persistence than the 'non-diabetic obesity' cohort in the existing claim because: (1) comorbid patients have stronger clinical motivation to continue, (2) the $50/month out-of-pocket cap removes financial barriers, and (3) these patients are already engaged with the healthcare system. If persistence is higher in this comorbid population, the chronic-use economics improve substantially.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries (tirzepatide starting April 2026), reducing the cost barrier by ~95% from typical commercial copays. This directly tests the affordability hypothesis: if discontinuation rates remain high even at $50/month OOP, it confirms non-financial factors dominate persistence. If discontinuation drops substantially, it confirms affordability is the primary driver.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-11-06
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: news
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
|
||||
EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare GLP-1 payment demonstration begins July 2026
|
||||
- BALANCE Model in Medicaid begins May 2026
|
||||
- BALANCE Model in Medicare Part D begins January 2027
|
||||
- Oral Wegovy launches January 2026 at $149-$299/month
|
||||
- Tirzepatide (Zepbound) $50/month OOP cap for Medicare beneficiaries starts April 2026
|
||||
- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria
|
||||
|
|
|
|||
Loading…
Reference in a new issue